The N6-methyladenosine reader IGF2BP2 in T-cell lymphoma.
- Open access
High IGF2BP2 expression drives tumor growth and immune evasion in PTCL, with overexpression observed in 3 independent cohorts and 196 patient samples.
- Why it matters: PTCL is a highly aggressive lymphoma lacking effective biomarkers and targeted therapies, making understanding its molecular drivers crucial for improving treatment options.
- What they did: The study used RNA-sequencing, in vitro, in vivo models, and patient-derived xenografts to investigate IGF2BP2’s role, revealing its regulation of endosome-related genes and impact on tumor proliferation and immune suppression.
- The result: Targeting IGF2BP2 with CWI1-2 suppressed endocytosis, reduced tumor growth, and offers a promising RNA modification-based therapeutic approach to simultaneously inhibit tumor progression and restore immune activity.